TORRALVA MEDICAL THERAPUETICS LLC

Portland, OR · Biotech · Private

Novel pharmacological antagonist for fentanyl-induced vocal cord closure and chest wall rigidity in opioid overdose

Grants
$699K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · I-Corps Project plan for:STTR Phase I Development of therapeutics to treat fentanyl overdose using a validated animal model$374,636
Federal grantDepartment of Health and Human Services · Phase I · Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.$324,196
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3161SYSTEM BIOSCIENCES, LLC (SBI)——
3162PACDNA LLC——
3163ANTEL BIOSYSTEMS, INC——
3164TORRALVA MEDICAL THERAPUETICS LLC——
3165Smart Biomolecules, Inc.——
3166IONIC PHARMACEUTICALS, LLC——
3167Sitryx Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.